BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36383901)

  • 1. Next-generation Sequencing as a Potential Diagnostic Adjunct in Distinguishing Between Desmoplastic Melanocytic Neoplasms.
    Roth A; Boutko A; Lampley N; Dhillon S; Hagstrom M; Olivares S; Dittman D; Jennings L; Santana Dos Santos L; Busam K; Gerami P
    Am J Surg Pathol; 2023 Mar; 47(3):318-325. PubMed ID: 36383901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benign and Intermediate-grade Melanocytic Tumors With BRAF Mutations and Spitzoid Morphology: A Subset of Melanocytic Neoplasms Distinct From Melanoma.
    Zhao J; Benton S; Zhang B; Olivares S; Asadbeigi S; Busam K; Gerami P
    Am J Surg Pathol; 2022 Apr; 46(4):476-485. PubMed ID: 34753863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression signature as an ancillary method in the diagnosis of desmoplastic melanoma.
    Clarke LE; Pimentel JD; Zalaznick H; Wang L; Busam KJ
    Hum Pathol; 2017 Dec; 70():113-120. PubMed ID: 29079183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted next generation sequencing (NGS) to classify melanocytic neoplasms.
    Zarabi SK; Azzato EM; Tu ZJ; Ni Y; Billings SD; Arbesman J; Funchain P; Gastman B; Farkas DH; Ko JS
    J Cutan Pathol; 2020 Aug; 47(8):691-704. PubMed ID: 32291779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical expression of p16 in desmoplastic melanoma.
    Blokhin E; Pulitzer M; Busam KJ
    J Cutan Pathol; 2013 Sep; 40(9):796-800. PubMed ID: 23808580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanocytic Skin Neoplasms: What Lesson From Genomic Aberrations?
    Urso C
    Am J Dermatopathol; 2019 Sep; 41(9):623-629. PubMed ID: 31433323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
    Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
    Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF and NRAS mutations in spitzoid melanocytic lesions.
    Fullen DR; Poynter JN; Lowe L; Su LD; Elder JT; Nair RP; Johnson TM; Gruber SB
    Mod Pathol; 2006 Oct; 19(10):1324-32. PubMed ID: 16799476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
    Bahmad HF; Oh KS; Alexis J
    J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of gene fusions in melanocytic neoplasms.
    Quan VL; Panah E; Zhang B; Shi K; Mohan LS; Gerami P
    J Cutan Pathol; 2019 Nov; 46(11):878-887. PubMed ID: 31152596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TERT Promoter Mutational Analysis as an Ancillary Diagnostic Tool for Diagnostically Challenging Melanocytic Neoplasms.
    Boutko A; Asadbeigi S; Roth A; Lampley N; Olivares S; Dittmann D; Dittmann D; Jennings L; Gerami P
    Am J Dermatopathol; 2023 May; 45(5):289-299. PubMed ID: 36898007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desmoplastic melanocytic nevi with lymphocytic aggregates.
    Kiuru M; Patel RM; Busam KJ
    J Cutan Pathol; 2012 Oct; 39(10):940-4. PubMed ID: 22845683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.
    Wiesner T; Kutzner H; Cerroni L; Mihm MC; Busam KJ; Murali R
    Pathology; 2016 Feb; 48(2):113-31. PubMed ID: 27020384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Desmoplastic Spitz nevus: a histopathological review and comparison with desmoplastic melanoma].
    Nojavan H; Cribier B; Mehregan DR
    Ann Dermatol Venereol; 2009 Oct; 136(10):689-95. PubMed ID: 19801251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma.
    Colebatch AJ; Paver EC; Vergara IA; Thompson JF; Long GV; Wilmott JS; Scolyer RA
    Pathology; 2022 Aug; 54(5):533-540. PubMed ID: 35248370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spitz nevi and Spitzoid melanomas: exome sequencing and comparison with conventional melanocytic nevi and melanomas.
    Lazova R; Pornputtapong N; Halaban R; Bosenberg M; Bai Y; Chai H; Krauthammer M
    Mod Pathol; 2017 May; 30(5):640-649. PubMed ID: 28186096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRAME immunohistochemistry of spitzoid neoplasms.
    Koh SS; Lau SK; Scapa JV; Cassarino DS
    J Cutan Pathol; 2022 Aug; 49(8):709-716. PubMed ID: 35488519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations.
    Piris A; Mihm MC; Hoang MP
    Hum Pathol; 2015 Feb; 46(2):239-45. PubMed ID: 25479927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S100A6 protein expression is different in Spitz nevi and melanomas.
    Ribé A; McNutt NS
    Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activating HRAS mutation in agminated Spitz nevi arising in a nevus spilus.
    Sarin KY; Sun BK; Bangs CD; Cherry A; Swetter SM; Kim J; Khavari PA
    JAMA Dermatol; 2013 Sep; 149(9):1077-81. PubMed ID: 23884457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.